Scholarlink

<p>The Pacific white shrimp (<i>Litopenaeus vannamei</i>) aquaculture faces emerging threats from novel pathogens and escalating antibiotic resistance. This study successfully isolated and identified the pathogenic bacterium <i>Acinetobacter ursingii</i> strain 31C2 from diseased <i>L. vannamei</i> using an integrated approach combining microbiological, biochemical, and molecular techniques. The pathogenicity of this strain was confirmed in <i>L. vannamei</i> and marine medaka (<i>Oryzias melastigma</i>) infection models, exhibiting a strong dose-dependent mortality, with median lethal doses (LD₅₀) of 2.83 × 10⁴ CFU/g shrimp and 2.58 × 10⁶ CFU/fish, respectively. Infection caused severe hepatopancreatic necrosis (tubular deformation and epithelial vacuolation) and intestinal villi destruction. Antimicrobial susceptibility testing revealed that the 31C2 strain was resistant to tetracycline and azithromycin. To identify effective agents targeting this strain, the antimicrobial peptide Scymicrosin<sub>7-26</sub> (derived from <i>Scylla paramamosain</i>) was evaluated. The peptide had potent antibacterial activity against <i>A. ursingii</i> 31C2 in vitro (MIC: 3–6 µM). In vivo application significantly enhanced survival of <i>L. vannamei</i> and <i>O. melastigma</i> infected with 31C2 by 30% and 20%, respectively. Treatment drastically reduced bacterial loads in the hepatopancreas and intestine, restored tissue integrity, and modulated the immune response by suppressing the hyperactivation of the Toll and IMD pathways and their downstream transcription factors, <i>dorsal</i> and <i>relish</i>, while upregulating <i>penaeidin3</i> and <i>propo</i> expression. This study identified <i>A. ursingii</i> as an emerging shrimp pathogen and validated Scymicrosin<sub>7-26</sub> as a promising antibiotic-free therapeutic for disease control in aquaculture.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Potential of Antimicrobial Peptide Scymicrosin7-26 against the Emerging Pathogen Acinetobacter ursingii Isolated from Litopenaeus vannamei

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Ying Wang,
  • Hanxiao Li,
  • Hua Hao,
  • Ying Zhou,
  • Fangyi Chen,
  • Ke-Jian Wang

摘要

The Pacific white shrimp (Litopenaeus vannamei) aquaculture faces emerging threats from novel pathogens and escalating antibiotic resistance. This study successfully isolated and identified the pathogenic bacterium Acinetobacter ursingii strain 31C2 from diseased L. vannamei using an integrated approach combining microbiological, biochemical, and molecular techniques. The pathogenicity of this strain was confirmed in L. vannamei and marine medaka (Oryzias melastigma) infection models, exhibiting a strong dose-dependent mortality, with median lethal doses (LD₅₀) of 2.83 × 10⁴ CFU/g shrimp and 2.58 × 10⁶ CFU/fish, respectively. Infection caused severe hepatopancreatic necrosis (tubular deformation and epithelial vacuolation) and intestinal villi destruction. Antimicrobial susceptibility testing revealed that the 31C2 strain was resistant to tetracycline and azithromycin. To identify effective agents targeting this strain, the antimicrobial peptide Scymicrosin7-26 (derived from Scylla paramamosain) was evaluated. The peptide had potent antibacterial activity against A. ursingii 31C2 in vitro (MIC: 3–6 µM). In vivo application significantly enhanced survival of L. vannamei and O. melastigma infected with 31C2 by 30% and 20%, respectively. Treatment drastically reduced bacterial loads in the hepatopancreas and intestine, restored tissue integrity, and modulated the immune response by suppressing the hyperactivation of the Toll and IMD pathways and their downstream transcription factors, dorsal and relish, while upregulating penaeidin3 and propo expression. This study identified A. ursingii as an emerging shrimp pathogen and validated Scymicrosin7-26 as a promising antibiotic-free therapeutic for disease control in aquaculture.